Cortechs.ai | Prediction of amyloid positivity using automated segmentation

Prediction of amyloid positivity using automated segmentation

Prediction of amyloid positivity in mild cognitive impairment using fully automated brain segmentation software

The objective of this study was to assess the predictive ability of regional volume information provided by fully automated brain segmentation software for cerebral amyloid positivity in mild cognitive impairment (MCI). (2020).

[button]Download[/button]

More Resources

05/18/2025

Cortechs.ai and ALZ-NET Announce Strategic Collaboration to Improve Alzheimer’s Disease Care Through AI-Driven Imaging

This new strategic collaboration aims to enhance the quality of care for people living with Alzheimer’s disease.

05/16/2025

Case Study: NeuroQuant® for ARIA: Monitoring ARIA Progression in Early Alzheimer’s Disease

Dr. Suzie Bash highlights how advanced imaging with NeuroQuant for ARIA supported detection and monitoring of ARIA-E and ARIA-H in an 81-year-old patient.

05/13/2025

Dr. Ana M. Franceschi Joins Cortechs.ai Medical Advisory Board

Neuroimaging thought leader to enhance PET/MRI and dementia research impact through AI-powered tools

05/10/2025

All the Ways to Use the NeuroQuant Custom Report

With the ability to select structures from NeuroQuant’s 70+ structure parcellation atlas, the user has the power to truly personalize patient care!

05/04/2025

Introducing NeuroQuant MS Lesion Dynamics Computation: A Clearer Path to Understanding Disease Progression

Discover how the latest NeuroQuant MS update offers a clearer, more intuitive way to track lesion changes and understand disease progression over time.

05/02/2025

4 Reasons Why Over 1500 Medical Centers Worldwide Trust Cortechs.ai

Trusted by 1500+ medical centers, Cortechs.ai delivers AI-powered imaging tools that enhance diagnostic accuracy and streamline workflows.
Scroll to Top